Hui Enland's New 250ml Balanced Salt Solution Approved, Expanding Ophthalmic Product Portfolio

(Source:Northland）

Recently, the balanced salt solution (for irrigation) developed by our holding subsidiary, Beijing Hui'en Land Pharmaceutical Co., Ltd.The 250ml specification has been officially approved by the National Medical Products Administration, with the approval number: H20269084. This product is suitable for use as an intraocular or extraocular irrigation solution during ophthalmic surgery and is one of the key consumables to ensure surgical safety and improve patient outcomes.

The approval of the 250ml specification, together with the already marketed 500ml specification, forms an effective complement, precisely meeting the dosage requirements of different ophthalmic surgeries. It provides a full range of high-quality, cost-effective localized solutions for clinical use, strongly breaking the long-term reliance on imported high-end ophthalmic irrigation products. As one of the few specialized enterprises in China focusing on the research and production of ophthalmic drugs, Northland continues to deepen its layout in the ophthalmology sector, with an increasingly enriched product portfolio and continuously optimized product structure. While providing more quality options for clinical use, it also injects new momentum into the steady improvement of the company’s operating performance.

Ophthalmic surgeries, especially delicate procedures like phacoemulsification for cataracts and vitreoretinal surgery, have extremely high requirements for the physicochemical properties of irrigation solutions. Traditional irrigation solutions, due to their composition,The pH and osmotic pressure differ significantly from those of human aqueous humor, which can easily lead to postoperative complications such as corneal edema and endothelial damage. As clinical requirements for surgical quality and safety continue to increase, specialized balanced salt solutions have become the recommended option in guidelines. The recently approved balanced salt solution (for irrigation) features a scientifically formulated composition that closely mimics the physiological environment of human aqueous humor in terms of pH, osmotic pressure, and ion composition. It effectively maintains the normal physiological functions of corneal endothelial cells and intraocular tissues, significantly reducing the risk of postoperative complications. In terms of production technology, this product utilizes an industry-leading "pouch-making, filling, and sealing" fully automated three-in-one production line, combined with dual-layer co-extruded membrane soft bag packaging. The entire process is highly automated, minimizing human intervention and contamination risks to ensure sterility. This fully demonstrates Hui En Lan De's leading strength in intelligent manufacturing within the field of ophthalmic pharmaceuticals.

Recently, Northland has been reporting good news frequently, with multipleThree products have been successively approved for clinical trials. The company’s product pipeline in the ophthalmology sector is becoming increasingly rich, the product structure is continuously optimized, and innovation capabilities as well as intelligent manufacturing levels are steadily improving. In the future, Huilan Biopharma will continue to focus on the ophthalmology field, developing more clinically accessible high-quality drugs to meet patients' medication needs, drive the company's operating performance to grow sustainably, and contribute to the high-quality development of China's ophthalmic healthcare industry.